


DARWIN EU® study

# Overall survival in patients with NSCLC treated with selected immunotherapies



## Why is this study needed?

Better understanding of lung cancer has led to new treatments, but more knowledge is needed on the effectiveness of medicines used to treat non-small cell lung cancer (NSCLC) in real-world settings. There has been insufficient evidence to inform assessments of new health technologies and how they work compared to existing alternatives.



## How were the results used?

The results show that people with NSCLC tend to live longer when treated with immunotherapy (particularly pembrolizumab), compared to chemotherapy when used as first treatment. This was after considering other factors that affect survival, such as age, sex, year of starting the treatment, tumour stage and patients' general wellbeing.



## How was this conducted?

Health technology assessment (HTA) bodies and payers requested the [study](#) to assess the overall survival of patients with locally advanced or metastatic NSCLC who start treatment with immunotherapies and how it compares to the survival of patients who get chemotherapies as first treatment. The study used data from 3 EU countries, including cancer registry data.



## Why do these results matter?

The first oncology study by DARWIN EU provides valuable insights into the effectiveness of immunotherapies versus chemotherapies in a real-world setting. Better understanding of lung cancer treatments is important because these therapies are expensive and increasingly used as the population ages and more people are diagnosed with lung cancer.

### More information



<https://catalogues.ema.europa.eu/>

© European Medicines Agency, 2026

Reproduction is authorised provided the source is acknowledged. For any use or reproduction of images or other materials that are not under the copyright of the European Medicines Agency as specified subsequently, permission must be sought directly from the respective copyright holders. The indicated images or other materials are copyright protected and have been licensed by the European Medicines Agency via Adobe Stock, Dreamstime or iStockphoto, as shown respectively in the credit lines of each image or other material.



[www.ema.europa.eu](http://www.ema.europa.eu)

An agency of the European Union

